MAM
InterMiles announces festive reward programme
Mumbai: Loyalty and rewards programme InterMiles on Friday announced its festive season sale called ‘InterMiles 300 Million Miles Festival.’ The festival will run for a total of three months including peak festive periods of Diwali, Christmas, and New Years, giving members more earnings and savings opportunities, it said.
The campaign will be amplified across YouTube, Facebook, and Instagram to educate existing and new members about the different ways in which they can engage with the programme and secure maximum value for their spends, said the brand in a statement.
“With the festive season around the corner and vaccination drives picking up pace across the country, consumer confidence is higher and discretionary spending is on the rise,” said InterMiles SVP of marketing and customer engagement Ashish Dhruva. “Through our 300 mn Miles Festival we want to reward members for these spends by ensuring that they not only spend smarter and save money but also end up creating a valuable miles fund for their future spends.”
The festive campaign includes five unique transactions of minimum Rs 2,000 each that can earn InterMiles members assured 15,000 miles. Members can engage with over 200 partners via the InterMiles Super App or the website across programme categories of flights, hotels, shop, dine, and vouchers, said the statement.
Members will also secure an assured 15 per cent discount on spends and a free upgrade to ‘Silver Tier’ which will give them a complimentary Zomato Pro or Amazon Prime membership plus free gift vouchers of up to Rs 500, it added.
“Our focus over the last few years has been on consolidating the InterMiles programme to offer our members a broader, more diverse category and partner portfolio to engage with. We have made Miles earnings attainable by broad basing opportunities to include daily lifestyle utilities and have balanced this by introducing multiple, quick micro and macro redemption options for our members to make the most of their miles,” Dhruva further said.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
